Incyte Corporation (INCY) Guidance & Earnings Results

On 2026-07-28 Incyte Corporation raised guidance: "FY2026 total net sales raised to $5,130-5,260M from $4,770-4,940M; Opzelura net sales raised to $1,050-1,100M from $750-790M; Hematology and Oncology net sales raised to $860-890M from $800-880M; Total GAAP R&D and SG&A…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

INCYIncyte CorporationFollow INCY — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 23.5B
P/E TTM: 14.7
Dividend yield: —
52-week: —
Next earnings: 29 Oct, in 5 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
28 Jul 26	Raised	FY2026 total net sales raised to $5,130-5,260M from $4,770-4,940M; Opzelura net sales raised to $1,050-1,100M from $750-790M; Hematology and Oncology net sales raised to $860-890M from $800-880M; Total GAAP R&D and SG&A operating expenses raised to $4,915-4,995M from $3,495-3,675M; Total Non-GAAP R&D and SG&A operating expenses raised to $4,625-4,695M from $3,205-3,375M · full year
10 Feb 26	Raised	FY2026 total net product revenue $4.77-4.94B; Jakafi $3.22-3.27B; Opzelura $750-790M; Hem/Onc $800-880M · full year
28 Oct 25	Raised	FY2025 net product revenue guidance raised to $4.23-$4.32B from prior · full year
29 Jul 25	Raised	FY2025 Jakafi net product revenues raised to $3,000-$3,050M from $2,950-$3,000M; FY2025 Other Oncology net product revenues raised to $500-$520M from $415-$455M; GAAP cost of product revenues updated to 8.0%-9.0% from 8.5%-9.0%; GAAP R&D expenses updated to $1,965-$1,995M from $1,930-$1,960M · full year

Incyte Corporation — questions

What guidance did Incyte Corporation give?: On 2026-07-28: "FY2026 total net sales raised to $5,130-5,260M from $4,770-4,940M; Opzelura net sales raised to $1,050-1,100M from $750-790M; Hematology and Oncology net sales raised to $860-890M from $800-880M; Total GAAP R&D and SG&A operating expenses raised to $4,915-4,995M from $3,495-3,675M; Total Non-GAAP R&"
When does Incyte Corporation report earnings?: Incyte Corporation's next earnings report is expected on 2026-10-29.

Every figure on this page comes from Incyte Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.